Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genzyme Tissue Repair - GZTR -- Ignore unavailable to you. Want to Upgrade?

To: Exacctnt who wrote (241)	9/15/1999 12:03:00 AM
From: Mark Adams	Respond to of 405

Long GZTR- Among the 44 patients receiving the highest dose of TGF-beta2, 61 percent achieved complete wound closure within 21 weeks. Among all the 131 patients receiving any dose of TGF-beta2, 59 percent achieved complete wound closure within 21 weeks. Among patients receiving placebo sponge, only 32 percent achieved complete wound closure during this same period of time. The non-blinded standardized care group achieved a 71 percent frequency of wound closure within 21 weeks. This level of efficacy with standardized care was unexpected, and is inconsistent with similar standardized care results published for other diabetic foot ulcer trials. It is believed that the observed result for standardized care in this trial is a statistical anomaly associated with the small number of patients in this group. This "anomaly" suggests that standard care works better than any of the sponge treatments. Clearly not conclusive.